RYAN CHO: Open Payments
NPI 1477070670 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,133 in 60 payments from 8 companies in 2025. Trend: 2023 $43 · 2024 $373 · 2025 $1,133
Food & beverage: $1,133
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 13 | $414 |
| AstraZeneca Pharmaceuticals LP | 6 | $211 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 18 | $172 |
| Exact Sciences Corporation | 14 | $159 |
| Lilly USA, LLC | 3 | $71 |
| Novo Nordisk Inc | 3 | $56 |
| Amgen Inc. | 2 | $34 |
| Astellas Pharma US Inc | 1 | $15 |
Products named: Kerendia, XIFAXAN, Cologuard Collection Kit, FARXIGA, AIRSUPRA, Ozempic, MOUNJARO, OTEZLA.
Industry payments across NV — which companies pay providers there.
